Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells
Figure 5
Representative images showing ablation of subcutaneous xenograft tumors by intraperitoneal ganciclovir (GCV) administration in nude mice. Thin arrow indicated xenograft tumors derived from control C6 cells, while thick arrow represented tumors that originated from either C6-TK cells (a) or C6-sr39TK cells (b). Although complete tumor ablation was not achieved, tumors in the mutant TK groups were significantly smaller than that from the wildtype TK or control group.
